Company news

Gilead Sciences, Inc. news in 2026

Gilead Sciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

April 21, 2026

Gilead Sciences Publishes 2025 Responsible Business and Impact Report, Highlighting Momentum Toward 2030 Ambitions

April 21, 2026

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

April 17, 2026

PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access

April 14, 2026

Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise

April 9, 2026

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

April 6, 2026

Gilead Extends Tender Offer to Acquire Arcellx

March 31, 2026

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

March 31, 2026

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

March 22, 2026

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

March 1, 2026

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

February 24, 2026

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

February 23, 2026

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

February 23, 2026

Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More

February 20, 2026

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

February 16, 2026

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

February 9, 2026

Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

February 9, 2026

FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma

February 5, 2026

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

January 27, 2026

4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer

January 22, 2026

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

January 20, 2026

← Newer news releases

Calls in 2026

Decks in 2026